Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nls Pharmaceutics Ltd (NQ: NLSP )

3.630 -0.230 (-5.96%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nls Pharmaceutics Ltd

< Previous 1 2 3 4 5 6 7 Next >
Why Adobe Is Trading Lower By 17%, Here Are 49 Stocks Moving In Thursday's Mid-Day Session
Gainers HeartBeam, Inc. (NASDAQ: BEAT) shares surged 58% to $1.96 after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome... 
Via Benzinga
NLS Pharmaceutics Appoints Dr. George Apostol as Chief Medical Officer and Global Head of Research & Development
Via ACCESSWIRE
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, trader! It's time to start off the day with a breakdown of the biggest pre-market stock movers for Tuesday morning! 
Via InvestorPlace
NLS Pharma Shares Fall After Mazindol ER Interim Data Shows 39% Improvement On Sleepiness Scale
Via Benzinga
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX... 
Via Benzinga
NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release
ZURICH, SWITZERLAND / ACCESSWIRE / July 28, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP), (Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the... 
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022
Upgrades 
Via Benzinga
NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release
Via ACCESSWIRE
Why XPeng Shares Traded Lower By Around 11%; Here Are 77 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning! We're starting the final day of trading this week with a look at the biggest pre-market stock movers for Friday! 
Via InvestorPlace
Why Windtree Therapeutics Is Trading Higher By Over 60%, Here Are 61 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
Why Guardforce AI is Trading Higher By 36%: Here's 24 Stocks Moving Premarket
Gainers 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 100 companies reached new 52-week lows. 
Via Benzinga
This Technology Stock Surged 235%; Here Are 77 Biggest Movers From Friday
Gainers 
Via Benzinga
NLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia
Via ACCESSWIRE
This Consumer Defensive Stock Is Trading Higher By Around 49%, Here Are 46 Stocks Moving In Friday's Mid-Day Session
Gainers Pagaya Technologies Ltd. (NASDAQ: PGY) shares gained 93% to $10.32. Pagaya Technologies is expected to announce its Q2 earnings on August 16, 2022. 
Via Benzinga
NLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia
ZURICH, SWITZERLAND / ACCESSWIRE / July 21, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery... 
From NLS Pharmaceutics AG
Via AccessWire
This Healthcare Stock Jumped 110%; Here Are 64 Biggest Movers From Yesterday
 Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares climbed 264% to close at $18.20 on Thursday. The company offered shares at an expected price of $5.00 per share with an insider lock-up period... 
Via Benzinga
NLS Pharmaceutics Announces Receipt of NASDAQ Minimum Bid Price Notification
ZURICH, SWITZERLAND / ACCESSWIRE / June 10, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the... 
From NLS Pharmaceutics AG
Via AccessWire
NLS Pharmaceutics Appoints Chad C. Hellmann as Chief Financial Officer
ZURICH, SWITZERLAND / ACCESSWIRE / June 6, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery... 
From NLS Pharmaceutics AG
Via AccessWire
Topics Bankruptcy Initial Public Offering
Exposures Financial Legal Securities Market
NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience(R) for the Treatment of Narcolepsy
ZURICH, SWITZERLAND / ACCESSWIRE / June 2, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery... 
From NLS Pharmaceutics AG
Via AccessWire
NLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience(R) Phase 2a Clinical Trial for Patients with Narcolepsy
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
NLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million Registered Direct Offering
ZURICH, SWITZERLAND / ACCESSWIRE / April 26, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the... 
From NLS Pharmaceutics AG
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
NLS Pharmaceutics to Participate in the B. Riley Annual Neuro & Ophthalmology Investor Conference
ZURICH, SWITZERLAND / ACCESSWIRE / April 22, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and... 
From NLS Pharmaceutics AG
Via AccessWire
NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
ZURICH, SWITZERLAND / ACCESSWIRE / April 13, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the... 
From NLS Pharmaceutics AG
Via AccessWire
NLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements
ZURICH, SWITZERLAND / ACCESSWIRE / April1, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery... 
From NLS Pharmaceutics AG
Via AccessWire
NLS Pharmaceutics Retains LifeSci Partners As Financial Advisor To Evaluate Strategic Partnering Initiatives
ZURICH, SWITZERLAND / ACCESSWIRE / March 31, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the... 
From NLS Pharmaceutics AG
Via AccessWire
NLS Pharmaceutics Announces Early Access Program (EAP) Allowing Patients with Idiopathic Hypersomnia to Receive Treatment with Mazindol ER
- Named Patient Program (NPP) enables physicians to prescribe the Company's novel Mazindol Extended-Release (ER) formulation to patients who have failed approved therapies - Product sales through the... 
From NLS Pharmaceutics AG
Via AccessWire
NLS Pharmaceutics to Participate in Maxim Group 2022 Virtual Growth Conference
ZURICH, SWITZERLAND / ACCESSWIRE / March 25, 2022 - NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and... 
From NLS Pharmaceutics AG
Via AccessWire
80 Biggest Movers From Yesterday
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares gained 86.7% to close at $0.5150 on Wednesday after the company announced FDA clearance of its IND for SON-... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.